Zika Virus, PCR, Molecular Detection, Random, Urine
Use
This test is useful for the qualitative detection of Zika virus RNA in paired urine and serum from individuals meeting the Centers for Disease Control and Prevention Zika virus clinical or epidemiologic criteria. It aids in diagnosing infections, particularly during the acute phase when RNA is most detectable. Zika virus is transmitted primarily through mosquito bites, but can also be transmitted through transfusion of blood, sexual contact, perinatally, and other means. Infections have been linked to severe congenital abnormalities and Guillain-Barre syndrome.
Special Instructions
Due to US Food and Drug Administration requirements, urine specimens must be tested in conjunction with a paired serum specimen. Testing for RNA or IgM-class antibodies to dengue and chikungunya viruses concurrently with Zika virus testing is strongly recommended to differentiate between these similar clinical presentations. Refer to the CDC guidelines for the most current recommendations.
Limitations
Negative reverse transcription polymerase chain reaction (RT-PCR) results do not rule out the possibility of Zika virus infection, as false negatives may occur due to RNA degradation or if samples are taken outside the window when RNA is typically present (within 7 days in serum and 14 days in urine post-symptoms). As such, negative results should be interpreted in conjunction with a patient's clinical history and potential exposure risks.
New York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
LOINC Codes
- 85623-7
- 85623-7
- 69048-7
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
1 mL
Minimum Volume
0.3 mL
Container
Sterile container
Collection Instructions
Collect random urine in a sterile container. Label specimen as urine.
Causes for Rejection
Urine containing preservatives
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 7 days |